Jade Biosciences, Inc. (JBIO) - Total Liabilities
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has total liabilities worth $22.97 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jade Biosciences, Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Jade Biosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Jade Biosciences, Inc. (JBIO) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Jade Biosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Jade Biosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gallant Micro Machining Co Ltd
TWO:6640
|
Taiwan | NT$2.71 Billion |
|
Huafa Industrial Co Ltd Zhuhai
SHG:600325
|
China | CN¥244.26 Billion |
|
Garcia Reguera S.A.
BA:REGE
|
Argentina | AR$4.61 Billion |
|
Cardinal Infrastructure Group Inc. Class A Common Stock
NASDAQ:CDNL
|
USA | $395.25 Million |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
China | CN¥231.83 Million |
|
Bonheur
OL:BONHR
|
Norway | Nkr15.88 Billion |
|
Altamir SCA
PA:LTA
|
France | €135.52 Million |
|
CW Enerji SA
IS:CWENE
|
Turkey | TL20.29 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Jade Biosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Jade Biosciences, Inc. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jade Biosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jade Biosciences, Inc. (2020–2025)
The table below shows the annual total liabilities of Jade Biosciences, Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $17.26 Million | +342.87% |
| 2024-12-31 | $3.90 Million | -78.30% |
| 2023-12-31 | $17.96 Million | +109.89% |
| 2022-12-31 | $8.56 Million | +190.59% |
| 2021-12-31 | $2.94 Million | +66.01% |
| 2020-12-31 | $1.77 Million | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more